ESTA Stock Overview
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.
Establishment Labs Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$57.60|
|52 Week High||US$93.80|
|52 Week Low||US$46.93|
|1 Month Change||-19.86%|
|3 Month Change||5.34%|
|1 Year Change||-16.55%|
|3 Year Change||119.43%|
|5 Year Change||n/a|
|Change since IPO||132.73%|
Recent News & Updates
|ESTA||US Medical Equipment||US Market|
Return vs Industry: ESTA matched the US Medical Equipment industry which returned -15.6% over the past year.
Return vs Market: ESTA underperformed the US Market which returned -10.4% over the past year.
|ESTA Average Weekly Movement||11.2%|
|Medical Equipment Industry Average Movement||10.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ESTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ESTA's weekly volatility (11%) has been stable over the past year.
About the Company
|2004||746||Juan Jose Chacon Quiros||https://www.establishmentlabs.com|
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
Establishment Labs Holdings Fundamentals Summary
|ESTA fundamental statistics|
Is ESTA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ESTA income statement (TTM)|
|Cost of Revenue||US$44.55m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.66|
|Net Profit Margin||-29.77%|
How did ESTA perform over the long term?See historical performance and comparison
Is Establishment Labs Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ESTA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ESTA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ESTA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: ESTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESTA is overvalued based on its PB Ratio (29.1x) compared to the US Medical Equipment industry average (2.5x).
How is Establishment Labs Holdings forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ESTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ESTA's is expected to become profitable in the next 3 years.
Revenue vs Market: ESTA's revenue (27.5% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: ESTA's revenue (27.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESTA's Return on Equity is forecast to be high in 3 years time
How has Establishment Labs Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ESTA is currently unprofitable.
Growing Profit Margin: ESTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ESTA is unprofitable, and losses have increased over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare ESTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESTA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).
Return on Equity
High ROE: ESTA has a negative Return on Equity (-83.88%), as it is currently unprofitable.
How is Establishment Labs Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ESTA's short term assets ($110.0M) exceed its short term liabilities ($36.5M).
Long Term Liabilities: ESTA's short term assets ($110.0M) exceed its long term liabilities ($57.2M).
Debt to Equity History and Analysis
Debt Level: ESTA's net debt to equity ratio (16.4%) is considered satisfactory.
Reducing Debt: ESTA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESTA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ESTA has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 6% each year.
What is Establishment Labs Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESTA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ESTA has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Juan Jose Chacon Quiros (49 yo)
Mr. Juan Jose Chacon Quiros Founded Establishment Labs, S.A. in 2004 and has been its Chief Executive Officer. Mr. Chacon Quiros has been Chief Executive Officer and Executive Director of Establishment Lab...
CEO Compensation Analysis
Compensation vs Market: Juan Jose's total compensation ($USD2.28M) is below average for companies of similar size in the US market ($USD5.45M).
Compensation vs Earnings: Juan Jose's compensation has increased whilst the company is unprofitable.
Experienced Management: ESTA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: ESTA's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Establishment Labs Holdings Inc.'s employee growth, exchange listings and data sources
- Name: Establishment Labs Holdings Inc.
- Ticker: ESTA
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$1.394b
- Shares outstanding: 24.20m
- Website: https://www.establishmentlabs.com
Number of Employees
- Establishment Labs Holdings Inc.
- Building B15 and 25
- Coyol Free Zone
- Costa Rica
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.